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Clearance of inhaled technetium-99m diethylenetriaminepentaacetate
(99mTc-DTPA) is a potential indicator of disease activity and progres-
sion in idiopathic pulmonary fibrosis (IPF). The objective of the pres-
ent study was to evaluate the prognostic value of 99mTc-DTPA scans
in IPF. A total of 22 patients (18 males), aged 33 to 80 years with IPF
were followed for six to 20 months (mean 13 months). At diagnosis,
high resolution computed tomography (HRCT) scans showed a
honeycomb pattern with bibasilar reticular opacities in all cases. At
T0 (diagnosis) and T1 (follow-up), each patient had pulmonary
function tests (forced vital capacity, diffusing capacity of the lung for
carbon monoxide and partial arterial O2 pressure), extension of
fibrosis evaluated by HRCT visual score and 99mTc-DTPA lung
clearance. Results at T0 and T1 were compared, taking into account
the whole population and patients with relatively fast and slow
99mTc-DTPA wash-out. 99mTc-DTPA clearance did not show any
significant correlation with functional tests or HRCT score. These
findings indicate that clearance of inhaled 99mTc-DTPA is not of
value in following the progress of IPF.
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La clairance du technétium-99m pentétate
permet-elle de prédire l’évolution clinique de
la fibrose pulmonaire idiopathique ?
La clairance du technétium-99m pentétate (99mTc-P) inhalé est un indi-
cateur potentiel de l’activité de la maladie et de son évolution en fibrose
pulmonaire idiopathique (FPI). La présente étude visait à évaluer la
valeur pronostique de tomodensitométries de 99mTC-P en cas de FPI. Au
total, 22 patients (18 hommes) de 33 à 80 ans souffrant de FPI ont été
suivis pendant six à 20 mois (moyenne de 13 mois). Au diagnostic, une
tomodensitométrie à haute résolution (THR) a révélé un profil alvéolaire
avec des opacités réticulaires bibasilaires dans tous les cas. Au T0 (diag-
nostic) et au T1 (suivi), chaque patient a subi des explorations fonction-
nelles respiratoires (capacité vitale forcée, capacité de diffusion
pulmonaire du monoxyde de carbone et pression partielle de l’oxygène
dans le sang artériel), une propagation de la fibrose évaluée par le score
visuel de la THR et une clairance pulmonaire du 99mTc-P. Les résultats au
T0 et au T1 ont été comparés, compte tenu de l’ensemble de la population
et des patients affichant une élimination relativement rapide ou lente du
99mTc-P. La clairance du 99mTc-P n’a pas révélé de corrélation significa-
tive avec les explorations fonctionnelles respiratoires ou le score de THR.
Ces observations indiquent que la clairance du 99mTc-P inhalé n’est pas
valable pour suivre la progression de la FPI.
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic pul-monary disease with poor prognosis (1,2). Currently, the rec-
ommended approach to stage and predict the progression of
IPF is based on pulmonary function tests (PFTs) and high reso-
lution computed tomography (HRCT) (3-5).
Technetium-99m diethylenetriaminepentaacetate
(99mTc-DTPA) aerosol clearance is a noninvasive index of pul-
monary epithelial permeability; increased permeability results
from inflammation of the lung parenchyma in a variety of dif-
fuse lung diseases (6). Test interpretation is based on the analy-
sis of radionuclide clearance after the isotope is administered as
a soluble aerosol, with a particle diameter of less than 2 µm, and
after cigarette smoking has been suspended for at least one week
(7-9). A clearance half-time of less than 50 min is considered to
be pathological and suggests diffuse interstitial damage (10,11).
Increased 99mTc-DTPA clearance has been cited as an early
marker of inflammation and activity grade (12,13).
The role of 99mTc-DTPA clearance in IPF is controversial;
according to some authors (13), the procedure should not be
recommended as a routine test in IPF, while other investigators
(14,15) have identified this technique as a significant predic-
tor of clinical course and survival.
The present study was designed to evaluate the potential of
99mTc-DTPA scans to assess disease activity and progression of
IPF. To assess the usefulness of 99mTc-DTPA scans, we prospec-
tively studied a group of IPF patients and compared the results
of this nuclear medicine test with HRCT quantitative scan-
ning and PFTs.
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METHODS
Twenty-two patients, 18 males and four females, aged 33 to
80 years (mean 66±10.5 years) (19 former smokers), diagnosed
with IPF on the basis of American Thoracic Society/European
Respiratory Society criteria (6), were studied and followed for a
period of six to 20 months (mean follow-up was 13 months).
HRCT scans revealed a honeycomb pattern with basal and
peripheral reticular opacities, and traction bronchiectasis in all
patients (16).
Patients were examined when stable, without signs of heart
failure or acute inflammation, on two occasions: at presentation
(T0) and at follow-up (T1). Patients had PFTs, and HRCT and
99mTc-DTPA scans. Informed consent was obtained from all
patients.
During the T0 to T1 interval, nine patients were treated with
corticosteroids (prednisolone 0.5 mg/kg/day for four weeks, fol-
lowed by 0.25 mg/kg/day for eight weeks and then followed by
0.125 g/kg/day for four to 12 weeks).
HRCT scans were performed with a single breath hold in the
prone position (17), without intravenous injection of contrast
material and using a filter for the osseous tissue. One millimetre
thick sections were taken, with a 1 s scan time and 10 mm intervals
between sections. Both lungs were included in the field of view.
The extent of the lesions was evaluated with a visual score and
expressed as a percentage of total lung volume, as previously
described (18).
PFTs were performed according to American Thoracic
Society guidelines (19). The following parameters were exam-
ined in all patients: partial arterial O2 pressure (PaO2) was deter-
mined using a Radiometer Abl 520 gas analyzer (Diamond
Diagnostic, USA) and expressed in mmHg; forced vital capacity
(FVC) was determined using a Morgan Transflow 544 pneumota-
chograph (Morgan Scientific, USA); and diffusing capacity of
the lung for carbon monoxide (DLCO) was determined using the
single breath method, with correction for hemoglobin values.
FVC and DLCO were expressed as percentages of the predicted
normal values (20).
The 99mTc-DTPA scans were performed by administering the
radionuclide as an aerosol from an Ultravent nebulizer
(Mallinckdrot Medical Inc, USA) consisting of particles 0.89 µm in
diameter. Scintigraphy was performed with a gammacamera,
equipped with a low energy general purpose collimator interfaced
to a computer. Patients were administered the aerosol for 3 min to
4 min in a closed circuit system and at normal tidal volume. At
the end of aerosol administration, chest images were immediately
recorded with the patient in the seated position. Each dynamic
image was acquired for 10 s in posterior projection on a
64×64 matrix, with a total acquisition time of 20 min. Regions of
interest were manually drawn around each lung and data were
processed to obtain time-activity curves. Clearance half-time was
calculated using a least squares curve fitting routine to find the
best exponential fit for the first 7 min of data because the contri-
bution of background activity was insignificant in this time inter-
val. A clearance half-time less than 50 min was considered to be
pathological.
Differences between T0 and T1 findings were investigated
using the Student’s t test for dependent variables, while the
Student’s t test for independent variables was used to compare the
findings between different groups. Correlations among HRCT
scores, pulmonary function studies and 99mTc-DTPA clearance
were analyzed using the two-tailed Pearson’s correlation coeffi-
cient. P<0.05 was regarded as significant.
RESULTS AND DISCUSSION
At presentation (T0), irregular opacities, prevailing at the
bases, were observed in all patients’ chest radiographs. All
patients showed a restrictive ventilatory impairment (Table 1).
DLCO values correlated significantly with both PaO2 (r=0.53,
P=0.021) and FVC (r=0.57, P=0.009) at T0. The extent of
parenchymal abnormalities evaluated with HRCT score
showed an inverse and significant correlation with PaO2
(r=–0.064, P=0.001), FVC (r=–0.047, P=0.023) and DLCO
(r=–0.046, P=0.028) at T0. Clearance of 99mTc-DTPA did not
show any significant relationship with the other parameters
considered, at either T0 or T1.
The extent of the lesions demonstrated by HRCT scan
showed a significant increase during the T0 to T1 interval; simi-
larly, a significant decrease in FVC, DLCO and PaO2 was
observed. A decrease in the extent of reticular opacities was
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TABLE 1
Pulmonary function studies, radiographic extent of
idiopathic pulmonary fibrosis and technetium-99m
diethylenetriaminepentaacetate (99mTc-DTPA) findings at
diagnosis (T0) and follow-up (T1) in the whole population
(n=22) 
T0 T1 P
HRCT score (%) 46.5±12.8 51.8±13.4 0.0013
(range 20.0 to 70.0) (range 28.5 to 75.0)
FVC (% pred) 69.8±18.6 64.8±16.7 0.0002
DLCO (% pred) 36.9±21.1 27.7±19.9 0.00003
PaO2 (mmHg) 75.0±14.5 68.7±15.2 0.0011
Clearance of 29.5±11.3 35.2±15.2 0.033
99mTc-DTPA (min)
Student’s t test for dependent variables. DLCO Diffusing capacity of the lung
for carbon monoxide; FVC Forced vital capacity; HRCT High resolution com-
puted tomography; PaO2 Arterial O2 pressure at rest; pred Predicted normal
value
TABLE 2
Pulmonary function studies and radiographic extent of
idiopathic pulmonary fibrosis at diagnosis (T0) and follow-up
(T1) in patients with markedly accelerated clearance (Cl)
of inhaled technetium-99m diethylenetriaminepentaacetate
(99mTc-DTPA) (group I) and patients with moderately
accelerated Cl of inhaled 99mTc-DTPA (group II) 
Group I Group II
T0 (Cl<25 min; n=10) (Cl>25 min; n=12)
HRCT scan score (%) 48.7±13.3 44.9±14.0
FVC (% pred) 67.8±20.6 69.8±18.3
DLCO (% pred) 38.1±18.8 35.4±24.8
PaO2 (mmHg) 76.9±10.3 73.2±17.8
T1 
HRCT scan score (%) 53.7±11.7 49.6±13.0 
FVC (% pred) 62.3±13.2 65.5±19.3 
DLCO (% pred) 24.8±14.1 30.3±23.2
PaO2 (mmHg)  66.5±15.6 70.1±13.1
Comparison of the two groups (Student’s t test for independent variables)
showed no significant differences at T0 or T1). DLCO Diffusing capacity of the
lung for carbon monoxide; FVC Forced vital capacity; HRCT High resolution
computed tomography; PaO2 Arterial O2 pressure at rest; pred Predicted nor-
mal value
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not observed in any patient. On the other hand, the clearance
of inhaled 99mTc-DTPA showed a significant slowing during the
T0 to T1 interval (higher and therefore less pathological values
of half-time) (Table 1).
Clearance of inhaled 99mTc-DTPA was less than 50 min in all
patients at T0. To investigate whether 99mTc-DTPA clearance at
presentation could be considered a predictive index of clinical
course, the patients were subdivided into two groups: patients
with a half-time clearance less than 25 min at T0 (group I, n=10)
and patients with a half-time clearance greater than 25 min at T0
(group II, n=12). Comparing the two groups at T0, PFTs and
HRCT scores showed no significant differences (Table 2).
During the T0 toT1 interval, a worsening of both radiolog-
ical and functional parameters was observed in both groups I
and II, although in patients with half-time clearance less than
25 min (group I), only DLCO and PaO2 changes were statisti-
cally significant. In patients with a half-time clearance greater
than 25 min (group II), all parameter changes were significant.
Further, at T1 there were no significant differences between
the two groups (Table 2). Therefore, the evolution of impair-
ment was very similar between the two groups. 
No correlations were found between 99mTc-DTPA clear-
ance and PFTs or HRCT quantitative scores at baseline, and
changes in HRCT and PFTs were not correlated with changes
in 99mTc-DTPA clearance values. Patients with more rapid
clearance at presentation did not show more functional or
radiological deterioration. In fact, clearance tended to
improve, while the other indexes worsened.
These results were not influenced by treatment because no
significant difference, in any considered parameter, was observed
between treated and untreated subjects, either at T0 or at T1
(data not shown).
Previous studies have investigated the role of 99mTc-DTPA
scans in the management of IPF patients; according to some
authors (14), a normal 99mTc-DTPA clearance at presentation
may predict stable lung function, while  accelerated clearance
may identify those cases that will further progress. However,
this study included a majority of patients with idiopathic inter-
stitial pneumonias other than IPF.
Recently, Mogulkoc et al (15) analyzed the 99mTc-DTPA
clearance in a considerable number of patients with significant
ground-glass opacities in the HRCT scan, thought to represent
IPF at an early stage. The authors identified 99mTc-DTPA
clearance as an independent predictor of survival, together
with age, total lung capacity and DLCO (15). However, clear-
ance was the least significant among the parameters consid-
ered, and did not correlate with PFTs or HRCT scores (15). A
prognostic role cannot be excluded, especially when the diag-
nosis of IPF is early; however, at present, these results may not
justify the use of an expensive and time-consuming technique
such as 99mTc-DTPA scans.
CONCLUSIONS
Although the small number of patients considered precludes
any definitive conclusion, our results suggest that 99mTc-DTPA
scans may be too expensive when compared with the informa-
tion supplied by other, less costly techniques. We conclude
that the use of 99mTc-DTPA scan is not of value in following
the progress of IPF, due to its poor predictive value on the clin-
ical course of this disease.
99mTc-DTPA clearance and idiopathic pulmonary fibrosis
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